Results 81 to 90 of about 49,657 (223)

A Novel Human Cellular System for Studying Normal Aging and for Anti‐Aging Discovery

Aging Cell, Volume 25, Issue 2, February 2026.
This study introduces a human cellular aging model using placental trophoblasts (hTSC‐STBs) that mimics key aging features like senescence and genomic instability. It aligns with human tissue aging and responds to anti‐aging treatments, offering a scalable platform to screen potential therapies and bridge lab findings to clinical applications ...
Zhen Feng, Cheuk Shuen Li, Haifeng Fu, Wenxin Jiang, Weiyu Zhang, Yingzhang Huang, Yunying Huang, Timothy Theodore Ka Ki Tam, Yang Li, Fang Liu, Liming Lu, Yin Lau Lee, William Shu Biu Yeung, Gordon Dougan, Pentao Liu   +14 more
wiley   +1 more source

Adaptive HIV-1 evolutionary trajectories are constrained by protein stability [PDF]

, 2017
Despite the use of combination antiretroviral drugs for the treatment of HIV-1 infection, the emergence of drug resistance remains a problem. Resistance may be conferred either by a single mutation or a concerted set of mutations.
Kandathil, Shaun M., Lovell, Simon C., Olabode, Abayomi S., Robertson, David L.   +3 more
core   +2 more sources

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe.
Jason D. Kim, Ingrid F. Metzger, Jessica Bo Li Lu, Todd C. Skaar, Zeruesenay Desta   +4 more
wiley   +1 more source

Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study

Journal of Microbiology, Immunology and Infection, 2017
Background/Purpose: Treatment response to switch regimens containing unboosted atazanavir and tenofovir disoproxil fumarate (TDF)/lamivudine guided by therapeutic drug monitoring in human immunodeficiency virus-infected patients is rarely investigated ...
Mao-Song Tsai, Sui-Yuan Chang, Shu-Wen Lin, Ching-Hua Kuo, Hsin-Yun Sun, Bin-Ru Wu, Sue-Yo Tang, Wen-Chun Liu, Yi-Ching Su, Chien-Ching Hung, Shan-Chwen Chang   +10 more
doaj   +1 more source

Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy

HIV Medicine, Volume 27, Issue 2, Page 217-225, February 2026.
Abstract Objective Evaluate factors associated with discontinuation of long‐acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) and describe virologic outcomes in those that returned to oral antiretroviral therapy (ART). Methods This is a retrospective cohort study at a single‐centre primary care HIV clinic.
Tali Faggiano, Jeffrey Yin, Nimish Patel, Afsana Karim, Kari Abulhosn, Laura Bamford, Lucas Hill   +6 more
wiley   +1 more source

Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort

BMC Infectious Diseases, 2005
Background The risk of hepatotoxicity associated with different highly active antiretroviral therapy (HAART) regimens (containing multiple-protease inhibitors, single-protease inhibitors or non nucleoside reverse transcriptase inhibitors) in HIV-HCV co ...
Caputo Sergio Lo, Mazzotta Francesco, Sotgiu Giovanni, Minoli Lorenzo, Ladisa Nicoletta, Pastore Giuseppe, Bella Daniele, Quiros-Roldan Eugenia, Nelson Mark, Puoti Massimo, Casari Salvatore, Lapadula Giuseppe, Torti Carlo, Di Perri Giovanni, Filice Gaetano, Tinelli Carmine, Carosi Giampiero   +16 more
doaj   +1 more source

HIV drug resistance prediction with weighted categorical kernel functions [PDF]

, 2019
Background: Antiretroviral drugs are a very effective therapy against HIV infection. However, the high mutation rate of HIV permits the emergence of variants that can be resistant to the drug treatment.
Belanche Muñoz, Luis Antonio, Pérez Enciso, Miguel, Ramon Gurrea, Elies   +2 more
core   +3 more sources

Bee products as alternatives in the treatment of viral infections

Journal of the Science of Food and Agriculture, Volume 106, Issue 1, Page 33-54, 15 January 2026.
Abstract Medicines used in the treatment of viral infections usually reduce symptoms. There is a need to develop drugs that inhibit the viruses and do not merely relieve the symptoms. Natural bee products possess many pharmacological properties and are widely used in folk medicine. There are many studies on the antibacterial effects of bee products but
Michał Otręba, Łukasz Marek, Jerzy Stojko, Anna Rzepecka‐Stojko   +3 more
wiley   +1 more source

The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study. [PDF]

, 2020
BACKGROUND:Understanding factors driving virological failure, including the contribution of HIV drug resistance mutations (DRM), is critical to ensuring HIV treatment remains effective.
Barnhart, Scott, Gilmore, Hailey J, Grignon, Jessica S, Hunt, Gillian, Liegler, Teri, Lippman, Sheri A, Mooney, Alyssa C, Prach, Lisa M, Puren, Adrian, Truong, Hong-Ha M   +9 more
core  

Managing Psychotropic Drugs with Efavirenz

Canadian Journal of Infectious Diseases and Medical Microbiology, 2006
Efavirenz is in the non-nucleoside reverse transcriptase inhibitor category of HIV antiretroviral medicines. It is an in vivo inducer of the CYP3A4 isoenzyme within the cytochrome P450 (CYP450) system, and an in vitro inhibitor of the system’s CYP2C9 ...
Rachel Therrien
doaj   +1 more source